As of November 6, 2026, Evotec SE is a publicly traded company (Nasdaq: EVO). The largest holder reporting an active stake on Schedule 13D is Excalibur LuxCo SARL, at 9.99%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, October 29, 2025).
Is this your company?
About to sign with, pay or invest in Evotec SE? See the free Snapshot first.
Free to see. No signup.
Is Evotec SE a real, registered company?
- Evotec SE files with the SEC under CIK 1412558 (its SEC filings).
- Its shares are listed under the ticker EVO on Nasdaq (also EVOTF) (SEC company record).
- Incorporated in 2M, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Evotec SE in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names MAK Capital Fund LP (filed 2026-05-01).
Who are Evotec SE's owners and officers?
Evotec SE: industry Pharmaceutical Preparations (Schedule 13D/A, 2026-10-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-10-14 | Mubadala Investment Company Pjsc | 0% |
| Schedule 13D/A, 2026-05-01 | Mak Capital Fund LP | 7.1% |
| Schedule 13D/A, 2026-04-06 | Mak Capital Fund LP | 7% |
| Schedule 13D, 2026-03-30 | Mak Capital Fund LP | 7% |
| Schedule 13G/A, 2026-02-17 | Novo Holdings A/S | 0% |
| Schedule 13G, 2026-01-16 | Mak Capital Fund LP | 5.3% |
| Schedule 13G/A, 2025-11-14 | Novo Holdings A/S | 5.3% |
| Schedule 13D/A, 2025-10-29 | Excalibur Luxco Sarl | 9.99% |
Questions about who owns Evotec SE
Who owns Evotec SE?
On this page, 2 holders' latest ownership filings report 5% or more of Evotec SE: Excalibur Luxco Sarl (9.99%, Schedule 13D/A, filed 2025-10-29) and Mak Capital Fund LP (7.1%, Schedule 13D/A, filed 2026-05-01).
Who are the largest shareholders of Evotec SE?
By the share each holder's latest filing reports, the largest holders of Evotec SE on this page are Excalibur Luxco Sarl (9.99%) and Mak Capital Fund LP (7.1%).
When did Excalibur Luxco Sarl buy into Evotec SE?
The filings give report dates, not purchase dates. The earliest filing from Excalibur Luxco Sarl on this page is the Schedule 13D/A, filed 2025-10-29, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Evotec SE?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Evotec SE: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Evotec SE covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
How much has Evotec SE raised?
No fundraising or offering filing from Evotec SE is on file with us.
Keep reading
More on Evotec SE and the records around it.
Evotec SE elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Mubadala Investment Company PJSC also filed stake reports on 5 other companies: GLOBALFOUNDRIES Inc. (Aug 2026), Blue Owl Technology Finance Corp. (Feb 2026), RECURSION PHARMACEUTICALS, INC. (Dec 2025)
- MAK Capital Fund LP also filed stake reports on 7 other companies: Comstock Inc. (Oct 2026), Autolus Therapeutics plc (May 2026), ClearPoint Neuro, Inc. (May 2026)
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/evotec-se